Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema and CRVO

• Status: Not yet recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tanta University
• Treatments: Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Patients fulfilling one or more of the following criteria will be considered to have resistant DME after at least 3 consecutive monthly anti VEGF injections in the previous 6 months:

• Central macular thickness greater than 300 μm by spectral-domain optical coherence tomography (SD-OCT).

• Reduction of retinal thickness by less than 10% of baseline retinal thickness.

• Suboptimal visual improvement (failure to gain at least 3 lines on the Snellen chart) and patients with recent onset central retinal vein occlusion less than 3 months.

Exclusion Criteria:

• Previous intraocular surgery (except cataract surgery done more than 6 months before the study).

• Coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration.

• Previous laser photocoagulation.

• Intravitreal injection of triamcinolone acetonide.

• Prior ocular inflammation.

• The presence of retinal degeneration.

• Patients who didnot complete 6 months of follow up